Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

AbbVie ( ABBV 0.61%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

By integrating AI and machine learning into the R&D process, the company aims to potentially cut the traditional 10- to 15-year timeline for ... for shareholders of Gilead Sciences (NASDAQ ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Gilead Sciences' cell therapy Kite Pharma has ... Xanthopoulos said the deal will "potentially accelerate Shoreline's timeline to the clinic, expand our pipeline opportunities and deliver ...

S&P 500 E-Mini futures are trending down -1.08% this morning as investors digest key U.S. inflation data and also await further testimony from Federal Reserve Chair Jerome P ...

A spokesperson for Advanz told pharmaphorum that, at the moment, the company does not have a timeline for when a ... Another potential option is Gilead Sciences PPAR agonist Livdelzi (seladelpar ...

Real-time index price for PHLX Housing Index (HGX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The stock's fall snapped a three-day winning streak.